Samuel Cholette-Tétrault

Dr. Samuel Cholette-Tétrault

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2024 in Family Practice
Verified
Journal Article
Closed access
PDF file
SCSamuel Cholette-Tétrault
Samuel Cholette-Tétrault
RGRoland Grad
Roland Grad
Background: Cannabinoid hyperemesis syndrome (CHS) is an increasingly recognized condition linked to chronic cannabis use, yet it remains frequently overlooked in clinical practice. The syndrome is characterized by cyclic episodes of severe nausea, vomiting, and abdominal pain, often relieved temporarily by hot showers or baths. With the rising prevalence of cannabis use following its legalization, the incidence of CHS has surged, presenting a significant challenge in both diagnosis and management within primary healthcare settings. Understanding the epidemiology, risk factors, and potential long-term sequelae of CHS is crucial for timely identification and intervention. This case report highlights the challenge of diagnosis and management of CHS in primary healthcare. Objective(s): To emphasize the importance of proper counseling and the use of Rome IV criteria in diagnosing CHS. To illustrate how this may reduce patient suffering and unnecessary investigation. Case: A 22-year-old female with chronic, daily cannabis use presented with recurrent episodes of intense nausea, vomiting, and abdominal pain over a 2-year period. Extensive diagnostic evaluations were inconclusive. A tentative diagnosis of CHS was made by a medical student and family doctor based on published criteria. The Rome IV criteria were then applied for confirmation of diagnosis and management. In so doing, the patient was advised to cease cannabis use for a minimum of 3 months. Initially, symptom improvement was reported with cannabis cessation. However, symptoms recurred following a relapse in cannabis use. Conclusion: To confirm the diagnosis of CHS, counseling should specify the need for a minimum of 3 months of cannabis cessation to achieve symptom relief. Increased physician and patient awareness of this minimal time period for drug cessation can help to avoid unnecessary investigations, and prolonged patient suffering. This case emphasizes the need for vigilance in recognizing CHS and consideration of cannabis as a potential cause of cyclic vomiting.

10 February 2026 in Healthcare
Verified
Journal Article
Open access
PDF file
SCSamuel Cholette-Tétrault
Samuel Cholette-Tétrault
PLPhilippe Leclerc
Philippe Leclerc
TBThomas Barabé-Tremblay
Thomas Barabé-Tremblay
MBMichaela Barbarosie
Michaela Barbarosie
Background: The clinical presentation of temporal lobe epilepsy (TLE) and panic disorder can sometimes overlap, particularly when the seizure symptoms include paroxysmal episodes of intense fear and autonomic symptoms. As a result, patients with TLE can be misdiagnosed with a primary psychiatric illness, which leads to inappropriate treatment, worsening of the underlying condition and decreased function and quality of life. Clinical case: We present the case of a 46-year-old woman, known for a 20-year history of generalized epilepsy and major depressive disorder with panic attacks that were refractory and persistent despite trials of SSRIs, benzodiazepines and cognitive behavioral therapy (CBT). While hospitalized for video-EEG monitoring in the context of worsening epilepsy, she was found to have TLE seizures presenting as what the patient had described as panic attacks, and that sometimes progressed to secondarily generalized seizures. Following a transition from a medication regimen targeting generalized epilepsy to one more appropriate for focal seizures, the patient experienced clinical improvement with a decrease in the magnitude and frequency of panic symptoms. Conclusions: This case, in combination with other case reports in the literature, demonstrates the need for clinical suspicion of TLE in patients presenting with atypical panic-like episodes or a refractory panic disorder, especially in cases known for epilepsy or having risk factors for seizure disorder. It also highlights the importance of comprehensive diagnostic evaluation in neuropsychiatric presentations, including EEG and brain imaging, to ensure accurate diagnosis and appropriate management.

12 August 2025 in Psychopharmacology Bulletin
Verified
Journal Article
Closed access
SCSamuel Cholette-Tétrault
Samuel Cholette-Tétrault
MBMehrshad Bakhshi
Mehrshad Bakhshi
In an article published on April 8, 2025 titled “A Case of Clozapine Induced Mania-Like Symptoms in the Treatment of Schizophrenia”,1 we recognized a clinical scenario similar to one we encountered in a 23-year-old African American male with no history of mania or hypomania who also appeared to have suffered mania-like symptoms from Clozapine initiation. At the time, Düşünen Adam was the only scientific journal presenting a case report and offering a possible mechanistic explanation via 5-HT2C, D4, and D1 receptor activation. It appears that the new publication in your journal agrees with their proposition as a probable explanation. In this present letter, we aim to propose further mechanisms to explain the suspected manicogenic properties of Clozapine. In addition to the mechanisms described in the published paper, we further hypothesize that, as shown with other atypical antipsychotics, selective blockade of 5-HT2A increasing dopamine in the mesolimbic pathway as well as the partial agonism of D2 and D3 by Norclozapine might contribute to the manic shift.2–6 Review of the literature and the mechanism of action of Clozapine and Norclozapine demonstrate action on many other targets in the brain, notably 5-HT1A agonism and muscarinic M1 antagonism.

20 October 2026 in OCL
Verified
Journal Article
Open access
SCSamuel Cholette-Tétrault
Samuel Cholette-Tétrault
APAdrien LeBlanc Piette
Adrien LeBlanc Piette
KFKarl Fernandes
Karl Fernandes
KZKevin Zemmour
Kevin Zemmour
SCStephen C. Cunnane
Stephen C. Cunnane
The human brain is energetically expensive in adults but even more so during early development. Current models of human brain energy metabolism remain largely glucocentric, with ketone bodies, mainly acetoacetate and β-hydroxybutyrate, often framed as secondary fuels used during fasting, starvation, or metabolic stress in adults. However, this perspective underestimates their physiological importance during early brain development. Here we re-examine the role of ketone bodies in brain development, with emphasis on their contribution to both energy metabolism and lipid synthesis. We performed a narrative synthesis of historical and contemporary literature on ketone uptake, oxidation, and anabolic metabolism in the developing brain, with a focus on studies in humans and animals that are rarely cited today and often poorly accessible online. The available evidence indicates that ketones are a significant substrate for ATP production in the infant brain and an important carbon source for the endogenous synthesis of cholesterol and fatty acids required for brain lipid formation. Impaired ketone availability, transport, or utilization may represent an underrecognized contributor to altered neurodevelopment and vulnerability to neurological and psychiatric disorders. Nutritional ketosis should therefore not be viewed only as an emergency metabolic state, but as a physiological feature of human brain development with therapeutic relevance across neurological and psychiatric disease.

13 July 2025 in Psychoactives
Verified
Journal Article
Open access
PDF file
SCSamuel Cholette-Tétrault
Samuel Cholette-Tétrault
NANissrine Ammari
Nissrine Ammari
MBMehrshad Bakhshi
Mehrshad Bakhshi
Canada’s national surveillance shows an 11% year-over-year decline in deaths from opioid and other unregulated drug poisonings, and a 10% drop in related hospitalisations in 2024. In stark contrast, Québec, home to more than nine million residents, and Montréal, the country’s second-largest city, experienced a continued rise in suspected drug-poisoning mortality through 2024, with fentanyl or analogues detected in almost two-thirds of opioid deaths. We conducted a narrative synthesis of provincial coroner and public-health surveillance tables, Health Canada dashboards, and the 2022–2025 Québec Strategy on Psychoactive-Substance Overdose Prevention. Results indicate a 40% increase in opioid-related mortality since 2018, a parallel uptick in stimulant toxicity, and a five-fold rise in overdose reversals at Montréal supervised-consumption services during the COVID-19 pandemic recovery. We aim to summarise the key problems underlying this epidemic and offer province-specific public-health strategies while also sending a call to action for first-line clinicians and psychiatrists to integrate overdose-risk screening, take-home naloxone, and stimulant-use-disorder treatments into routine care. We further urge Québec healthcare professionals to deepen their knowledge of provincial services such as supervised-injection sites and stay up to date with the rapidly evolving substance-use-prevention literature. Québec’s divergent trajectory underscores the need for region-tailored harm-reduction investments and stronger policy-to-clinic feedback loops to reduce preventable deaths.